{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:34:45Z","timestamp":1788863685143,"version":"build-2803163510"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:p>Primary adrenal diffuse large B-cell lymphoma (PA-DLBCL) is rare. We investigate 23 Japanese patients with PA-DLBCL to understand the clinicopathologic features and biological behavior of this disease. The 17 males and 6 females had a median age of 74 years (range: 40 to 86\u2009y). Tumor cells harbored Epstein-Barr virus\u2013encoded small RNA (EBER) in 9 (39%) samples, including samples from the 2 patients with methotrexate-associated B-cell lymphoproliferative disorder. Programmed cell death ligand 1 (PD-L1) expression was detected in tumor cells of 6 (26%) samples, including 1 EBER<jats:sup>+<\/jats:sup> and 5 EBER<jats:sup>\u2212<\/jats:sup> samples. Four (17%) patients exhibited an intravascular proliferating pattern, and all 4 patient samples showed positive staining for PD-L1 in tumor cells. Among those patients, 3 showed intravascular proliferating pattern accompanied by a diffuse extravascular proliferation of tumor cells, and 1 patient was diagnosed with intravascular large B-cell lymphoma. We divided the 23 patients into 3 groups: EBER<jats:sup>+<\/jats:sup> (n=9, 39%), EBER<jats:sup>\u2212<\/jats:sup>PD-L1<jats:sup>+<\/jats:sup> (n=5, 22%), and EBER<jats:sup>\u2212<\/jats:sup>PD-L1<jats:sup>\u2212<\/jats:sup> (n=9, 39%). A comparison of the outcomes among the 3 groups showed significant differences in overall survival (<jats:italic toggle=\"yes\">P<\/jats:italic>=0.034). The EBER<jats:sup>+<\/jats:sup> group had the worst prognosis, and the EBER<jats:sup>\u2212<\/jats:sup>PD-L1<jats:sup>\u2212<\/jats:sup> group had the best prognosis. We also compared the outcomes among the 3 groups that received rituximab-containing chemotherapies. Both the overall survival and progression-free survival were significantly different among these groups (<jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.001 and <jats:italic toggle=\"yes\">P<\/jats:italic>=0.002, respectively). In conclusion, we evaluated 3 types of PA-DLBCL and found that each had unique clinical, pathologic, and prognostic features. Our results suggested that immune senescence, iatrogenic immunodeficiency, and immune evasion contribute to the development of PA-DLBCL.<\/jats:p>","DOI":"10.1097\/pas.0000000000001809","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T19:33:32Z","timestamp":1631907212000},"page":"1606-1615","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma"],"prefix":"10.1097","volume":"45","author":[{"given":"Tasuku","family":"Kawano","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital"},{"name":"Diagnostic Pathology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Tsuyuki","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Hematology and Oncology, Nagoya University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Takahara","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Aichi Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Nakaguro","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Sakakibara","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nagoya University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Satou","sequence":"additional","affiliation":[{"name":"Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Aichi Prefecture, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"R1-20250608","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11864-018-0555-8","article-title":"Cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence","volume":"19","author":"Ollila","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"R2-20250608","first-page":"534","article-title":"Malignant lymphoma of the adrenal gland: its possible correlation with the Epstein-Barr virus","volume":"9","author":"Ohsawa","year":"1996","journal-title":"Mod Pathol"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/modpathol.2009.87","article-title":"Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis","volume":"22","author":"Mozos","year":"2009","journal-title":"Mod Pathol"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1756-8722-5-49","article-title":"Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)","volume":"5","author":"Kim","year":"2012","journal-title":"J Hematol Oncol"},{"key":"R5-20250608","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2162-3619-2-19","article-title":"Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis","volume":"2","author":"Ichikawa","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00277-013-1812-3","article-title":"Primary adrenal lymphoma: a systematic review","volume":"92","author":"Rashidi","year":"2013","journal-title":"Ann Hematol"},{"key":"R7-20250608","first-page":"103","article-title":"Adrenal lymphoma: presentation, management and prognosis","volume":"110","author":"Laurent","year":"2017","journal-title":"QJM"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00428-018-2378-1","article-title":"Primary adrenal diffuse large B cell lymphoma: a clinicopathological and molecular study from China","volume":"473","author":"Zhang","year":"2018","journal-title":"Virchows Arch"},{"key":"R9-20250608","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00277-019-03740-9","article-title":"Clinical characteristics and outcomes of primary adrenal diffuse large B cell lymphoma in a large contemporary cohort: a SEER-based analysis","volume":"98","author":"Li","year":"2019","journal-title":"Ann Hematol"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/PAS.0000000000001386","article-title":"Morphologic patterns and the correlation with MYD88 L265P, CD79B mutations in primary adrenal diffuse large B-cell lymphoma","volume":"44","author":"Chen","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R11-20250608","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1080\/10428194.2020.1725507","article-title":"Clinico-pathological characteristics of primary adrenal lymphomas\u2014potential efficacy of autologous stem cell transplantation","volume":"61","author":"Narazaki","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2147\/OTT.S133385","article-title":"Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies","volume":"10","author":"Ilcus","year":"2017","journal-title":"Onco Targets Ther"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","article-title":"PD-1 and PD-L1 antibodies in cancer: current status and future directions","volume":"66","author":"Balar","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"9513701","DOI":"10.1155\/2019\/9513701","article-title":"Immune checkpoint inhibition in classical hodgkin lymphoma: from early achievements towards new perspectives","volume":"2019","author":"De Goycoechea","year":"2019","journal-title":"J Oncol"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1182\/bloodadvances.2018020602","article-title":"PD-L1 and tumor-associated macrophages in de novo DLBCL","volume":"3","author":"McCord","year":"2019","journal-title":"Blood Adv"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/bloodadvances.2018027672","article-title":"MYD88 L265P mutation and CDKN2A loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas","volume":"3","author":"Nayyar","year":"2019","journal-title":"Blood Adv"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"e1626653","DOI":"10.1080\/2162402X.2019.1626653","article-title":"High tumoral PD-L1 expression and low PD-1(+) or CD8(+) tumor-infiltrating lymphocytes are predictive of a poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system","volume":"8","author":"Kim","year":"2019","journal-title":"Oncoimmunology"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s00428-019-02695-6","article-title":"Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas","volume":"476","author":"Alame","year":"2020","journal-title":"Virchows Arch"},{"key":"R25-20250608","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/neup.12705","article-title":"Expression of programmed cell death ligand-1 by immune cells in the microenvironment is a favorable prognostic factor for primary diffuse large B-cell lymphoma of the central nervous system","volume":"41","author":"Tsuyuki","year":"2021","journal-title":"Neuropathology"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00535-019-01616-3","article-title":"Prognostic impact of PD-L1 expression in primary gastric and intestinal diffuse large B-cell lymphoma","volume":"55","author":"Ishikawa","year":"2020","journal-title":"J Gastroenterol"},{"key":"R27-20250608","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/PAS.0000000000001499","article-title":"Reappraisal of primary epstein-barr virus (EBV)-positive diffuse large B-cell lymphoma of the gastrointestinal tract: comparative analysis among immunosuppressed and nonimmunosuppressed stage I and II-IV patients","volume":"44","author":"Miyagi","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/PAS.0000000000000983","article-title":"PD-L1 and PD-L2 are differentially expressed by macrophages or tumor cells in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"42","author":"Menguy","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/pin.12742","article-title":"Immune evasion-related extranodal large B-cell lymphoma: a report of six patients with neoplastic PD-L1-positive extranodal diffuse large B-cell lymphoma","volume":"69","author":"Suzuki","year":"2019","journal-title":"Pathol Int"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2016-02-698936","article-title":"PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia\/lymphoma","volume":"128","author":"Miyoshi","year":"2016","journal-title":"Blood"},{"key":"R31-20250608","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1440-1827.2006.01936.x","article-title":"Prevalence of Epstein-Barr virus in Japan: trends and future prediction","volume":"56","author":"Takeuchi","year":"2006","journal-title":"Pathol Int"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/pathogens7010028","article-title":"EBV-positive lymphoproliferations of B- T- and NK-cell derivation in non-immunocompromised hosts","volume":"7","author":"Dojcinov","year":"2018","journal-title":"Pathogens"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/00000478-200301000-00003","article-title":"Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients","volume":"27","author":"Oyama","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"R35-20250608","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2015-02-630632","article-title":"EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment","volume":"126","author":"Nicolae","year":"2015","journal-title":"Blood"},{"key":"R36-20250608","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-06-2823","article-title":"Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients","volume":"13","author":"Oyama","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R37-20250608","doi-asserted-by":"crossref","first-page":"4726","DOI":"10.1182\/blood-2010-12-323238","article-title":"Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma","volume":"117","author":"Dojcinov","year":"2011","journal-title":"Blood"},{"key":"R38-20250608","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/modpathol.2012.52","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation","volume":"25","author":"Montes-Moreno","year":"2012","journal-title":"Mod Pathol"},{"key":"R39-20250608","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"R40-20250608","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"R41-20250608","doi-asserted-by":"crossref","first-page":"e23173","DOI":"10.1002\/jcla.23173","article-title":"Adrenal diffuse large B-cell lymphoma with high PD-L1 expression: two case reports and literature review","volume":"34","author":"Chen","year":"2020","journal-title":"J Clin Lab Anal"},{"key":"R42-20250608","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1002\/cam4.3104","article-title":"PD-L1 (SP142) expression in neoplastic cells predicts a poor prognosis for patients with intravascular large B-cell lymphoma treated with rituximab-based multi-agent chemotherapy","volume":"9","author":"Suzuki","year":"2020","journal-title":"Cancer Med"},{"key":"R43-20250608","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J Clin Oncol"},{"key":"R44-20250608","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/hon.2090","article-title":"Phenotype profiling of primary testicular diffuse large B-cell lymphomas","volume":"32","author":"Menter","year":"2014","journal-title":"Hematol Oncol"},{"key":"R46-20250608","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R47-20250608","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/his.13765","article-title":"Integrative analysis of PD-L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B-cell lymphoma","volume":"74","author":"Sun","year":"2019","journal-title":"Histopathology"},{"key":"R48-20250608","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s00428-020-02901-w","article-title":"Clinicopathological analysis of neoplastic PD-L1-positive EBV(+) diffuse large B cell lymphoma, not otherwise specified, in a Japanese cohort","volume":"478","author":"Takahara","year":"2021","journal-title":"Virchows Arch"},{"key":"R50-20250608","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-Cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001809","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:06:37Z","timestamp":1749416797000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001809"}},"subtitle":["A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells"],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001809","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,16]]}}}